The predictive value of preprocedural laboratory data in patients with coronary artery restenosis in various types of stents
https://doi.org/10.15829/1560-4071-2019-3-54-59
Abstract
Aim. To identify the effect of preprocedural laboratory parameters on the occurrence of in-stent restenosis in various types of stents, to assess the significance of gender, age and various forms of coronary artery disease (CAD) as risk factors for coronary artery restenosis after stenting.
Material and methods. The study included 436 patients with CAD, which were divided into 2 groups. The study group included 218 patients with in-stent restenosis. The control group consisted of 218 patients with CAD without in-stent restenosis. Inclusion criteria were acute or chronic form of CAD, age 45-74 years, CAG and percutaneous coronary intervention (PCI) with emergency or planned stenting of the native coronary artery, repeated CAG in history due to signs/symptoms of myocardial ischemia. Exclusion criteria: age younger than 45 years and over 74 years, coronary artery bypass surgery (CABG), cancer, autoimmune disease, anemia, liver failure, chronic kidney disease S4-S5, recent blood transfusion, hypo-or hyperthyroidism.
Results. According to the study, the risk in-stent restenosis is 5,2 times higher in patients in the 65-69 years age group and 9,9 times higher in the 70-74 years age group compared with the group of young patients (45-49 years). In-stent restenosis is 2,7 times more common in men than in women. Predictors of restenosis were red cell distribution width, mean platelet volume, Gensini score with OR 1,5; 1,4; 1,1; 1,5, respectively.
Conclusion. Risk factors for coronary artery restenosis after stenting are markers of chronic inflammation, such as the red cell distribution width, mean platelet volume. The risk of restenosis is higher in the male population. In old age, the risk of restenosis increases, however, young people and middle-aged people do not differ in risk of in-stent restenosis.
About the Authors
D. V. ShamesRussian Federation
Kazan
A. S. Galyavich
Russian Federation
Kazan
Z. M. Galeeva
Russian Federation
Kazan
L. V. Baleeva
Russian Federation
Kazan
References
1. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320-31. doi:10.1093/eurheartj/ehv511.
2. Kurtul A, Murat SN, Yarlioglues M, et al. The association of red cell distribution width with in-stent restenosis in patients with stable coronary artery disease. Platelets. 2015;26:48- 52. doi:10.3109/09537104.2014.881990.
3. Turak O, Ozcan F, Isleyen A, et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol. 2012;110:1405-10. doi:10.1016/j.amjcard.2012.07.003.
4. Norgaz T, Hobikoglu G, Aksu H, al. The relationship between preprocedural platelet size and subsequent in-stent restenosis. Acta Cardiol. 2004;59:391-5. doi:10.2143/AC.59.4.2005204.
5. Yılmaz S, Sen F, Ünal S, et al. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. Scand Cardiovasc J. 2015;49(1):39-44. doi:10.3109/14017431.2014.989537.
6. Samko AN, Merkulov EV, Vlasov VM, et al. Restenosis: causes and mechanisms of development with different types of endovascular treatment. Atherosclerosis and dyslipidemias. 2014;1:5-8. (In Russ.)
7. Veselovskaya NG, Chumakova GA, Suvorova AA, et al. Gender differens risk factors restenosis of coronary arteries after stenting at patients with obesity. Modern issues of science and education. 2012;5:64. (In Russ.)
8. Gençbay M. Do pre-procedural laboratory parameters predict drug-eluting stent restenosis? Turk Kardiyol Dern Ars. 2015;43(5):417-9. doi:10.5543/tkda.2015.71340.
9. Niccoli G, Montone RA, Ferrante G, et al. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56:1783-93. doi:10.1016/j.jacc.2010.06.045.
10. Tanındı A, Ekici B, Töre HF. Do pre-procedural laboratory parameters predict drugeluting stent restenosis? Turk Kardiyol Dern Ars. 2015;43(5):457-64. doi:10.5543/tkda.2015.48275.
11. Demirkol S, Balta S, Celik T, et al. Assessment of the relationship between red cell distribution width and cardiac syndrome X. Kardiol Pol.2013;71:480-4. doi:10.5603/KP.2013.0094.
12. Lippi G, Filippozzi L, Montagnana M, et al. Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes. Clin Chem Lab Med 2009;47:353-7.
13. Yildiz A, Tekiner F, Karakurt A, et al. Preprocedural red blood cell distribution width predicts bare metal stent restenosis. Coron Artery Dis 2014;25:469-73. doi:10.1097/MCA.0000000000000105.
14. Akin F, Kose N, Ayca B, et al. Relation between red cell distribution width and severity of coronary artery disease in patients with acute myocardial infarction. Angiology 2013;64:592-6. doi:10.1177/0003319712461931.
15. Iijima R, Ndrepepa G, Mehilli J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007;154:688-93. doi:10.1016/j.ahj.2007.06.005.
Review
For citations:
Shames D.V., Galyavich A.S., Galeeva Z.M., Baleeva L.V. The predictive value of preprocedural laboratory data in patients with coronary artery restenosis in various types of stents. Russian Journal of Cardiology. 2019;(3):54-59. (In Russ.) https://doi.org/10.15829/1560-4071-2019-3-54-59